Q-omics provides the consensus-scored TTC3 profile across patient tissues and cancer cell-line models. TTC3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TTC3 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, TTC3 RNA expression shows 21,156 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where TTC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC3 survival associations across molecular data types. TTC3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC3 RNA expression–survival associations across cancer types. High TTC3 expression shows unfavorable associations in ACC, UVM, MESO and SARC, but favorable associations in HNSC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TTC3 RNA expression.
This table summarizes TTC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC3 shows lower tumor expression in KICH and KIRC and higher tumor expression in LUAD, LIHC, CHOL and LUSC. The LUAD box plot shows higher TTC3 RNA expression in tumor versus normal tissue (log2 FC = +0.704, t-test p < 0.001).
This table shows molecular features associated with TTC3 in patient tissues and cancer cell lines. In patient samples, TTC3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
